| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 10/13/2004 | EP1466902A1 Androgen receptor antagonists |
| 10/13/2004 | EP1466901A1 Serotonine reuptake inhibitor |
| 10/13/2004 | EP1466900A1 2-substituted vitamin d derivatives |
| 10/13/2004 | EP1466891A1 Carboxylic acid derivative |
| 10/13/2004 | EP1466889A1 Derivatives of venlafaxine and methods of preparing and using the same |
| 10/13/2004 | EP1466888A1 Calcium receptor-active arylalkyl amines |
| 10/13/2004 | EP1466649A1 Pharmaceutical composition containing artificial oxygen carrier |
| 10/13/2004 | EP1466641A1 Treatment of pulmonary vasoconstriction and asthma |
| 10/13/2004 | EP1466631A1 Preparations appropriate for cartilage tissue formation |
| 10/13/2004 | EP1466628A1 DHA-pharmaceutical agent conjugates |
| 10/13/2004 | EP1466627A1 Polyglutamate camptothecin conjugates |
| 10/13/2004 | EP1466626A1 Medicinal compositions for improving oral absorption |
| 10/13/2004 | EP1466625A1 Preventives/remedies for urinary disturbance |
| 10/13/2004 | EP1466614A1 Polypeptide, the conjugate thereof containing doxorubicine and a pharmaceutical composition based thereon |
| 10/13/2004 | EP1466609A1 Method of preparing and using isoflavones |
| 10/13/2004 | EP1466608A1 Herbal composition comprising Angelica gigantis, Cnidium officinale and Paeonia japonica |
| 10/13/2004 | EP1466607A1 Compositions for the treatment of primary and metastatic neoplastic diseases using arsenic compounds in combination with all-trans retinoic acid |
| 10/13/2004 | EP1466606A2 Use of inosine for the manufacture of a medicament for stimulating axonal outgrowth of central nervous system neurons |
| 10/13/2004 | EP1466605A2 Calcium channel blockers |
| 10/13/2004 | EP1466604A1 Isoquinoline derivatives, process for their preparation and use thereof in the treatment of melatoninergic system problems |
| 10/13/2004 | EP1466603A2 Novel catechols as antimicrobial agents |
| 10/13/2004 | EP1466602A1 Organ fibrosis inhibitors |
| 10/13/2004 | EP1466601A2 Prevention of migraine recurrence |
| 10/13/2004 | EP1466600A1 Ready-to-use oxaliplatin solutions |
| 10/13/2004 | EP1466599A1 Concentrated solution of oxaliplatinum |
| 10/13/2004 | EP1466598A2 PDE-IV inhibitors |
| 10/13/2004 | EP1466597A1 Use of dha esters to control or prevent cardiovascular diseases |
| 10/13/2004 | EP1466595A1 Apparatus and process for preparing crystalline particles |
| 10/13/2004 | EP1466594A2 Stable pharmaceutical solution formulations for pressurised metered dose inhalers |
| 10/13/2004 | EP1466590A1 Cosmetic use of new desquamative agents |
| 10/13/2004 | EP1466585A2 Use of of aminosubstituted hydroxybenzophenones as photostable UV-filter in cosmetic and pharmaceutical preparations |
| 10/13/2004 | EP1466526A2 Microbicidal composition |
| 10/13/2004 | EP1466175A2 SPHKs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE |
| 10/13/2004 | EP1466174A2 Mutations in the bcr-abl tyrosine kinase associated with resistance to sti-571 |
| 10/13/2004 | EP1465998A2 Single nucleotide polymorphisms predicting cardiovascular disease and medication efficacy |
| 10/13/2004 | EP1465995A1 Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same |
| 10/13/2004 | EP1465914A1 Triterpene quaternary salts as biologically active surfactants |
| 10/13/2004 | EP1465912A2 Novel chimeric tnf ligands |
| 10/13/2004 | EP1465908A2 Compositions and methods for hydroxylating epothilones |
| 10/13/2004 | EP1465906A1 Compositions and methods relating to endometrial specific genes and proteins |
| 10/13/2004 | EP1465901A2 Processes for desolvating solvates of atorvastatin hemi-calcium and atorvastatin hemi-calcium essentially free of organic solvent |
| 10/13/2004 | EP1465900A1 Rho-kinase inhibitors |
| 10/13/2004 | EP1465899A1 Trioxane derivatives |
| 10/13/2004 | EP1465898A1 Biocidal compounds and their preparation |
| 10/13/2004 | EP1465896A2 Mitotic kinesin inhibitors |
| 10/13/2004 | EP1465895A2 4-oxo-4,7-dihydrofuro(2,3-b)pyridine-5-carboxamide antiviral agents |
| 10/13/2004 | EP1465894A2 Synthesis and purification of valacyclovir |
| 10/13/2004 | EP1465893A1 Derivatives of 5-(pyridin-3-yl)-1-azabicyclo (3.2.1) octane, the preparation thereof and the application of same in therapeutics |
| 10/13/2004 | EP1465892A1 Glycinamides as factor xa inhibitors |
| 10/13/2004 | EP1465891A2 Inhibitors of dipeptidyl peptidase iv |
| 10/13/2004 | EP1465890A1 Stable lansoprazole containing more than 500 ppm, up to about 3,000 ppm water and more than 200 ppm, up to about 5,000 ppm alcohol |
| 10/13/2004 | EP1465889A1 Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| 10/13/2004 | EP1465888A2 Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues |
| 10/13/2004 | EP1465887A1 Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical compositions containing the novel forms and methods for treating nausea using them |
| 10/13/2004 | EP1465886A1 Bipyridinyl derivatives as a highly selective cyclooxygenase-2 inhibitor |
| 10/13/2004 | EP1465885A2 Novel alkyl/aryl hydroxy or keto thiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (asbt) and taurocholate uptake |
| 10/13/2004 | EP1465880A1 5-sulphanyl-4h-1,2,4-triazole derivatives and their use as medicine |
| 10/13/2004 | EP1465878A1 Alkynylated fused ring pyrimidine compounds as matrix metalloprotease-13 inhibitors |
| 10/13/2004 | EP1465876A1 Long chain fatty alcohol substituents in antineoplastic agents |
| 10/13/2004 | EP1465875A1 Novel alkansulfonamides as endothelin antagonists |
| 10/13/2004 | EP1465872A1 4-sulfide/sulfoxide/sulfonyl-1h-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor |
| 10/13/2004 | EP1465871A1 Pyrazole derivatives for use in diseases associated with the 5-ht2c receptor |
| 10/13/2004 | EP1465870A2 Substituted 4-phenyltetrahydroisoquinolinium salts, method for production and use thereof as a medicament and medicaments comprising the same |
| 10/13/2004 | EP1465869A1 Modulators of lxr |
| 10/13/2004 | EP1465868A1 Phenoxy piperidines for treating diseases such as schizophrenia and depression |
| 10/13/2004 | EP1465867A1 Ligands of melanocortin receptors and compositions and methods related thereto |
| 10/13/2004 | EP1465866A2 Protease inhibitors of the coagulation cascade isolated from dysidea sponges |
| 10/13/2004 | EP1465864A1 Inhibitors of factor xa and other serine proteases involved in the coagulation cascade |
| 10/13/2004 | EP1465863A1 Potassium channel modulators |
| 10/13/2004 | EP1465862A1 Cycloalkyl ketoamides derivatives useful as cathepsin k inhibitors |
| 10/13/2004 | EP1465861A1 Alpha-(n-sulphonamido)acetamide derivatives as beta-amyloid inhibitors |
| 10/13/2004 | EP1465860A4 An improved process for the synthesis of ( ) 2-amino-n-[2,(s,5-dimethoxyphenyl)-2-hydroxyethyl] acetamide monohydrochloride |
| 10/13/2004 | EP1465860A1 An improved process for the synthesis of ( ) 2-amino-n-[2,(s,5-dimethoxyphenyl)-2-hydroxyethyl] acetamide monohydrochloride |
| 10/13/2004 | EP1465858A2 Pheny(alkyl)carboxylic acid derivatives and dionic phenylalkylheterocyclic derivatives and their use as medicines with serum glucose and/or serum lipid lowering activity |
| 10/13/2004 | EP1465854A2 Chalcone derivatives and their use to treat diseases |
| 10/13/2004 | EP1465852A1 Synthesis of combretastatin a-2 prodrugs |
| 10/13/2004 | EP1465699A1 Photophoretic auto immune stimulation |
| 10/13/2004 | EP1465670A2 Labeling targeting agents with gallium-68 and gallium-67 |
| 10/13/2004 | EP1465667A2 Screening and selection methods for statin drug combinations |
| 10/13/2004 | EP1465666A2 Multicomponent assemblies having enhanced binding properties for diagnosis and therapy |
| 10/13/2004 | EP1465665A1 Water-soluble stabilized self-assembled polyelectrolytes |
| 10/13/2004 | EP1465663A1 Ready-to-use paracetamol injection solutions containing propylene glycol as the only cosolvent |
| 10/13/2004 | EP1465662A1 Combination treatments for allergic disease comprising administering an anti-ige antibody and antiallergic compound |
| 10/13/2004 | EP1465661A1 Cancer treatment |
| 10/13/2004 | EP1465646A1 Bioavailability enhancing activity of zingiber officinale linn and its extracts/fractions thereof |
| 10/13/2004 | EP1465645A1 A novel herbal chemical composition for the treatment of cancer |
| 10/13/2004 | EP1465642A1 Protection against the neurotoxicity of oxaliplatin through the administration of calcium and magnesium |
| 10/13/2004 | EP1465640A1 Use of polysaccharide derivatives as anti-infective substances |
| 10/13/2004 | EP1465638A2 Phosphate transport inhibitors |
| 10/13/2004 | EP1465637A1 25-hydroxy vitamin d3 compositions |
| 10/13/2004 | EP1465636A2 Compositions and methods for enhancing corticosteriod delivery |
| 10/13/2004 | EP1465635A2 Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1h-benzoimidazole analogues |
| 10/13/2004 | EP1465634A2 Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation |
| 10/13/2004 | EP1465633A1 Quinazolinone compounds in combined modalities for improved cancer treatment |
| 10/13/2004 | EP1465632A1 Quinazoline derivatives for the treatment of abnormal cell growth |
| 10/13/2004 | EP1465631A2 Pyrimidine a2b selective antagonist compounds, their synthesis and use |
| 10/13/2004 | EP1465630A1 Cyclic urea derivatives with 5-ht2c receptor activity |
| 10/13/2004 | EP1465629A1 5-ht3 receptor antagonists and methods of use |
| 10/13/2004 | EP1465628A2 Fine particle size pioglitazone |
| 10/13/2004 | EP1465627A1 DOSING REGIMEN FOR PPAR−GAMMA ACTIVATORS |